Compare Clorox Co (CLX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Pfizer Inc — how do they compare? Clorox Co trades at $108.39 (market cap $13.02B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 11.8× Clorox Co's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| CLX | PFE | |
|---|---|---|
Market Cap | $13.02B | $154.18B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $28.56 |
52-Week Low | $86.12 | $23.60 |
Enterprise Value | $18.40B | $205.67B |
Dividend Yield | 4.64% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.15, down 0.43% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.66, though Q4 2025 missed. The company reported fiscal 2025 revenue of $7.10 billion and net income of $810 million, with a high ROE of 285.64% but elevated P/B ratio of 141.28. Dividend increased to $1.25 per share, payable August 28, 2026.
Outlook is mixed: bullish technicals and profitability contrast with analyst caution (10.34% buy ratings) and a consensus price target of $97.50 below current price. Risks include inflation pressures and competitive threats from private labels. Upside hinges on execution of cost-saving initiatives and market share recovery.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
